European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

Development of a rapid cellular characterisation technology <br/>for use in the biopharmaceutical Industry

Objetivo

"Biopharmaceuticals have universal importance as effective therapeutics for many human diseases. Biopharmaceutical production employs living cells as ‘production machinery’ with the selection of the producing cell line, a critical step for an efficient industrial process. Current industry practices for cell selection are expensive and time-consuming. The proposed PM-CELL project will result in the development of a rapid cellular characterisation testing technology. The two-year project will result in an innovative 96-well micro-titre plate containing a unique array of analytes, which can be used to accelerate development and reduce manufacturing costs of biopharmaceuticals synthesised by mammalian cell lines. A successful project would result in cost savings for the SMEs’ customers in the bioprocessing industry and a more rapid translation of research to efficient drug production for human healthcare. The project would result in generation of a high value (economic and intellectual property) technology which would result in increased sales and assets to the SMEs. The SMES will then be well placed to take advantage of further development opportunities in the biopharmaceutical industry, which is actively looking for innovative solutions for manufacturing-cell selection in drug production."

Convocatoria de propuestas

FP7-SME-2011
Consulte otros proyectos de esta convocatoria

Régimen de financiación

BSG-SME - Research for SMEs

Coordinador

TECHNO-PATH DISTRIBUTION
Aportación de la UE
€ 499 999,38
Dirección
FORTHENRY BUSINESS PARK
BALLINA
Irlanda

Ver en el mapa

Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Contacto administrativo
Guy Mozolowski (Dr.)
Enlaces
Coste total
Sin datos

Participantes (7)